Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

<table>Kaplan-Meier plot of overall survival (OS) in 36 patients treated with biweekly gemcitabine and docetaxel. Median OS was 4.2 months (95% CI: 2.4–7.0 months). The 6-month OS rate was 40% (95% CI: 24–56%). The 12-month OS rate was 16% (95% CI: 3–28%).</table>

International Scholarly Research Notices

fig2

Figure 2

Figure 2: Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 

Figure 2 | Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 